Regulatory Bayer gets swift review for Kerendia in type 1 diabetes PharmaphorumFDA starts a priority review of Bayer's Kerendia for chronic kidney disease in type 1 diabetes, which could end a 30-year drought in new therapies.Metabolic & GLP-1Read full story pharminent May 21, 2026 (Last updated: May 21, 2026) Pharmaphorum FDA starts a priority review of Bayer’s Kerendia for chronic kidney disease in type 1 diabetes, which could end a 30-year drought in new therapies. Metabolic & GLP-1 Read full story Please leave this field emptySign up to receive free daily digest Check your inbox or spam folder to confirm your subscription. Post navigation Previous: ATS 2026: PABPC4 gene identified as a key driver of emphysema in COPDNext: FUJIFILM opens new iPSC facility in Madison, US Related Stories Regulatory Novo Nordisk comeback stirs as Wegovy pill wins UK approval pharminent June 12, 2026 Regulatory Lilly wins new FDA approval for eczema drug Ebglyss pharminent June 10, 2026 Regulatory Disc’s FDA meeting sets ‘clear path’ for embattled rare blood disease drug pharminent June 10, 2026
